CaSki Cells

Unit

3 x 10^6 cells/ml

Cell Type

Tumor Cells

Tissue Type

Reproductive system cancer cell lines

Organism

Human

Donor History

Carcinoma

Growth Properties

Adherent

Growth Conditions

Culture medium: RPMI 1640

,

w: 2.0 mM stable Glutamine

,

w: 2.0 g/L NaHCO3 (Cytion article number 820700a). Supplements: Supplement the medium with 10% FBS. Dissociation reagent: Accutase. Seeding density: 1 x 10⁴ cells/cm² will result in a confluent monolayer within 3to4 days. Freeze medium: As a cryopreservation medium

,

we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability

,

or CM-1 (Cytion catalog number 800100)

,

which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C

,

5% CO2

,

humidified atmosphere.

Immortalization Method
Full Information

https://www.cytion.com/CaSki-Cells/300145

SKU: 300145 Kategorie: ,
Mgr. Otakar Fišer
Máte otázky k tomuto produktu? Kontaktujte našeho specialistu.
Mgr. Otakar Fišer
Produktový manažer - Life Science
Popis

CaSki is a cell line exhibiting epithelial morphology, isolated from the cervix of a 40-year-old White female patient with epidermoid carcinoma. The establishment of this cell line provides a critical model for the study of cervical cancer, particularly in the context of HPV-mediated oncogenesis. CaSki cells are characterized by their capacity to replicate HPV16 DNA, which is integrated into the host’s genome, offering insights into the viral life cycle and its role in malignant transformation.

These cells are an essential resource in cancer research, particularly for studies focusing on the pathogenesis of HPV-associated cervical cancer. The presence of high-risk HPV16 in CaSki cells facilitates the exploration of viral oncogene functions, notably the E6 and E7 proteins and their interactions with cellular tumor suppressor pathways, including those involving p53 and pRB. This aspect makes CaSki cells invaluable for evaluating potential therapeutic targets and developing interventions aimed at HPV-induced malignancies.

O značce

Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.

Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.